Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 9/20 | 0.79 |
| ▸ | DBF4 | Q9UBU7 | 9/20 | 0.79 |
| ▸ | TRPM8 | Q7Z2W7 | 7/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | RARA | P10276 | 1/20 | 0.55 |
| ▸ | RARB | P10826 | 1/20 | 0.55 |
| ▸ | RARG | P13631 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15049215 | 0.89 | CDC7 (0.79) | CDC7DBF4TRPM8MAPT | |
| SCHEMBL8324969 | 0.88 | CDC7 (1.00) | CDC7DBF4TRPM8 | |
| SCHEMBL15049029 | 0.86 | CDC7 (0.67) | CDC7DBF4TRPM8ALDH1A1HSD17B10 | |
| SCHEMBL17374877 | 0.85 | TRPM8 (0.75) | CDC7DBF4TRPM8MAPT | |
| SCHEMBL4811904 | 0.85 | CDC7 (0.73) | CDC7DBF4TRPM8ALDH1A1HSD17B10 | |
| SCHEMBL1316281 | 0.85 | CDC7 (0.77) | CDC7DBF4TRPM8ALDH1A1HSD17B10 | |
| SCHEMBL4503056 | 0.83 | CDC7 (0.88) | CDC7DBF4TRPM8ALDH1A1HSD17B10 | |
| SCHEMBL6338322 | 0.83 | TRPM8 (1.00) | CDC7DBF4TRPM8MAPT | |
| SCHEMBL4163499 | 0.83 | SMN1; SMN2 (0.64) | CDC7DBF4TRPM8ALDH1A1MAPT | |
| SCHEMBL23702797 | 0.82 | CDC7 (0.73) | CDC7DBF4TRPM8ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| WO-2007089031-A1 | PIPERIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | CDC7 3202/4885DBF4 2822/4885TRPM8 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.